AstraZeneca Slaps Biovail Over Seroquel XR

Law360, New York (January 13, 2009, 12:00 AM EST) -- In its latest bid to protect two patents for Seroquel XR, AstraZeneca Pharmaceuticals LP has hit Biovail Corp. and two subsidiaries with an infringement suit over the popular treatment for bipolar disorder and schizophrenia.

The complaint, filed Friday in the U.S. District Court for the District of New Jersey, alleges that Biovail's submission of an abbreviated new drug application for an extended-release version of quetiapine fumarate to the U.S. Food and Drug Administration infringes AstraZeneca's patents.

The patents-at-issue are U.S. Patent Numbers 4,879,288 and 5,948,437, which...
To view the full article, register now.